Medical Excellence Capital, LLC

We are thrilled to celebrate 22q Awareness Day together with Nobias Therapeutics and highlight the exciting opportunity for NB-001! The team at Nobias, led by Patrick Dougherty, has focused its resources on its development programs following receipt of positive data from a multi-center, randomized, double blind, placebo-controlled Phase 2 clinical trial of its lead asset, NB-001, for the potential treatment of the neuropsychiatric symptoms associated with 22q11 deletion syndrome (22q11DS), the most common human microdeletion.

Just Released: BENS Member Insights on #Biotechnology's Security Frontier As the biotech sector advances, there is a need for public-private collaboration to stay ahead of potential security risks. In this piece, industry leaders Patrice Bonfiglio, Ansbert Gadicke, M.D., and John Prufeta share their perspectives on managing dual-use advancements, securing #innovation, and more. Dive into their insights on the rapid evolution of biotech and its implications for national security?? https://bit.ly/4fBSEgs #nationalsecurity | #biotech | #supplychains | Sarissa Capital Management LP | MPM Capital | Medical Excellence Capital, LLC

"#Biotechnology is rapidly evolving into a critical arena for #nationalsecurity, with innovations that have profound long-term implications already beginning to emerge.?" Business Executives for National Security (BENS) interviewed MEC Founder & General Partner John Prufeta together with Patrice Bonfiglio and Ansbert Gadicke, M.D. highlight several key action items to ensure the secure advancement of biotechnology including: 1. Strengthen #PublicPrivate Partnerships: Enhance collaboration between government agencies and private biotech firms to foster innovation while maintaining robust security measures. 2. Implement Comprehensive #BiosecurityPolicies: Develop and enforce policies that address potential biosecurity threats, ensuring that advancements in biotechnology do not compromise national security. 3. Invest in #WorkforceDevelopment: Allocate resources to train and educate professionals in biotechnology, universities, researchers, and biosecurity, creating a skilled workforce capable of navigating the complexities of the field. 4. Promote #EthicalResearch Practices: Encourage ethical standards in biotech research to prevent misuse and ensure that developments align with societal values and security concerns. 5. Enhance #Domestic Biotechnology Manufacturing: The United States should prioritize domestic production capabilities and reduce reliance on foreign suppliers. 6. Leverage #AdvancedTechnologies: Utilize emerging technologies, such as artificial intelligence and machine learning, to monitor and mitigate biosecurity risks effectively. By focusing on these areas, stakeholders and policymakers can navigate the challenges at the intersection of biotechnology innovation and security, ensuring that advancements benefit society while safeguarding against potential threats. Read the full article here: https://lnkd.in/es-NcUYg

Our company was created to deploy capital that results in the development of great biotech companies. However, we also think of ourselves as citizens of the the industry we serve and the country in which we live. As a result, each of us at MEC volunteer our time to help “make a material difference in the lives of our fellow beings”. Medical Excellence Capital Founder and General Partner John Prufeta recently was interviewed for a thought piece on BioTech and National Security. Please read on…

?? The MEC Q3 2024 Newsletter went out this week! Read more about MEC's focus on execution, our recent annual meeting, significant progress at our portfolio companies, and exciting science within our MEC Network. Check it out on our MEC Blog page: https://lnkd.in/e47vS3c3 "Execution is the key differentiator between breakthrough success and failure, especially in biotech. As the late Brian Dovey emphasized in his book, 'The Idea is the Easy Part – Myths and Realities of the Startup World', the challenge lies in mastering execution. In life sciences, it is not enough to have a groundbreaking idea—success comes from the ability to adapt, prioritize, and manage the nearly endless complexities of bringing a therapy to market" Click here to subscribe to our newsletter: https://eepurl.com/hSIgP9 #biotech #venturecapital #lifesciences #pharma #startups

?? The MEC Q3 2024 Newsletter went out this week! Read more about MEC's focus on execution, our recent annual meeting, significant progress at our portfolio companies, and exciting science within our MEC Network. Check it out on our MEC Blog page: https://lnkd.in/e47vS3c3 "Execution is the key differentiator between breakthrough success and failure, especially in biotech. As the late Brian Dovey emphasized in his book, 'The Idea is the Easy Part – Myths and Realities of the Startup World', the challenge lies in mastering execution. In life sciences, it is not enough to have a groundbreaking idea—success comes from the ability to adapt, prioritize, and manage the nearly endless complexities of bringing a therapy to market" Click here to subscribe to our newsletter: https://eepurl.com/hSIgP9 #biotech #venturecapital #lifesciences #pharma #startups

Medical Excellence Capital, LLC Holds Third Annual Meeting So delighted to share that MEC held its third annual meeting last week, hosted at the NEW YORK STOCK EXCHANGE. The MEC Team reported on the Fund’s results since last year, as well as our vision for the coming years. With 9 companies in the portfolio and 6 in the clinic, naturally our theme this year focused on - EXECUTION. That is, how do we put MEC’s substantial resources of relationships, Intelligence, and network to work in a way that materially impacts our portfolio companies. MEC LPs, we exist because of you. Thank you for your support. Execution in action is exactly why we invited 5 portfolio CEOs to join us at the NYSE to present their firm’s progress, challenges, and partnership with MEC. Thank you, Stan Abel (ProJenX); Patrick Dougherty (Nobias Therapeutics); Parastoo Khoshakhlagh, Ph.D. (GC Therapeutics); Damien McDevitt (Aspen Therapeutics); and Jay Srinivasan (Truvian). Rick Hartz, Merck President of Global Pharma and Commercial Development was kind to join in-person to provide viewpoints on Pharma industry trends as well as areas of scientific innovation and interest. He provided valuable insights about how Merck engages with the scientific, entrepreneurial, and investment communities. Rick, we are in your debt, thank you!. Thanks to our Scientific Advisory Board members that were present, Olga Troyanskaya (Princeton) and Doug Wallace (CHOP). Your contributions were much appreciated by our investors. Olga, we embrace your vision of computational biology’s current and future impact on drug discovery and health! Doug, your passion for Mitochondria as prime mover in understanding and curing disease is infectious. All participants of the meeting were confirmed “Mitochondriacs”! Thanks to SAB members Euan Ashley (Stanford), Gregg Semenza (Nobel Laureate, John’s Hopkins), and Stephen Tsang, MD, PhD (Columbia) for joining remotely! Keynote Speaker Asmeret Asghedom, Deputy Director of Lawrence Livermore National Laboratory, provided a compelling presentation on Global Energy and National Security implications. Asmeret, you are a star. As citizens, we are grateful to you for your dedicated thought leadership in service to the USA. NYSE, thank you for hosting us! Your site is incomparable! Special thanks to Johanna Grossman, PhD, NYSE Head of Life Sciences and Health Care Capital Markets. A great friend. Eric J. Dimise, PhD, Sector Head presented the NYSE strategy for Life Sciences. we learned of NYSE’s strategy of supporting smaller, pre-revenue Life Sciences companies to join the Big Board. Given the very substantial resources of the NYSE, this is welcome news to companies and the VCs that back them! Innovative! Thanks, Eric, great presentation! Thanks to my unequaled teammates at MEC - Brian Halak, Eric Heil, Kim Kamdar, Joni Mancini, Max Colbert MD, MBA, Olga Prufeta (Gouroudeva), John P. Hornbostel, Annabel Stoddart, Tess Marvin and Jasmin Revanna TRULY A GREAT DAY!

Long-time MEC friend Bridget Martell posted lovely commentary on the wrap-up session for lat week’s Life Sciences Summit. Thank you, Bridgett! My pleasure as well. The sum of the wrap-up was the general feeling of marked optimism for the science, markets, and most importantly, for the patients! Thanks to my colleagues on the panel, I certainly learned from them. Thanks also to Diane Fabel and Clint Rubin for organizing a top-level conference!

MEC managing partner, Eric Heil, together with Dennis Purcell, Lori Gough, Bruce S. and Gaeton Biscardi shared some investor perspectives and excitement for what the state of Pennsylvania and the Life Sciences Pennsylvania team is doing to support the vibrant life science ecosystem. “There is a real sense of community here!” - Dennis “Survive to 2025, Fixed by 2026, Heaven in 2027?”

We were thrilled to collaborate and support the many talented leaders and researchers at Mayo Clinic Ventures as they continue to push the boundaries of medical innovation and patient-centric care. It’s inspiring to see such dedication to advancing healthcare and improving lives worldwide! #HealthcareInnovation #Leadership #Research #MayoClinic #HealthcareTransformation #precisionmedicine